Latest News Archive

Please select Category, Year, and then Month to display items

Sona 2023: Let us not confuse indifference with apathy

07 February 2023 | Story Dr Ina Gouws | Photo Supplied

Opinion Article by Dr Ina Gouws, Senior Lecturer: Programme: Governance and Political Transformation, Department of Political Studies and Governance, University of the Free State.

The State of the Nation Address (Sona) of 2023 is upon us. What can South Africans look forward to in this address this year? According to the Presidency, the President will focus on the energy crisis and the rolling blackouts. He will hopefully also shed some light on the disaster legislation government intends to implement to address the energy crisis. Reports that the ANC wants Dr Nkosazana Dlamini-Zuma to oversee the load-shedding state of disaster does not inspire confidence at the onset. What we should take serious note of is what the President will have to say about the plans to move Eskom to the Department of Mineral Resources and Energy; a move widely criticised and frankly, feared.

No new policies, focus on resolving policy implementation failures

Also, according to the Presidency, the outcomes of the Investing in Africa Mining Indaba taking place from 7 February 2023, will receive attention in the Sona. This event attracts more than 6 000 delegates comprising comprising investors, innovators, companies in the mining and natural resources sector etc. No doubt the President will paint a picture of substantial investments to look forward to which will lead to job creation, development, and growth; a promise made in every Sona of every year of his term without fail, for which there has been very little evidence.

The Minister in the Presidency, Mondli Gungubele, also told the media that government will not look to introduce new policies but focus on resolving existing policy implementation failures since this is the final year of this government’s term.

Other than these areas of focus, we can surely expect the usual stats and figures to indicate “progress” or evidence of a caring government; more people receiving social grants instead of no longer needing this assistance, and entirely unrealistic job creation numbers to name two. Collapsing municipalities and ongoing corruption will also probably get mentioned under the umbrella of service delivery with futile promises of eradicating corruption and appointing qualified cadres. This administration’s score card of the past four years justifies cynicism.

From what I have heard among fellow South Africans and seen on social media, the interest in the Sona is at an all-time low because of the miseries mentioned. We are tired of politicians talking, promising, stating the obvious (a particular skill our President has polished) and blatantly underestimating our collective intelligence. We KNOW there is no concrete plan to address the energy crisis. We SEE incompetent ministers still have jobs. Promises for growth and job creation do not resonate at all because South Africans LIVE THE REALITY of unemployment and poverty. South Africans cannot be blamed when the idea of sitting through an address covering more of the same with no expectation of positive change is something we are not prepared to do.

Indifference towards Sona 2023

Does this indifference towards the Sona this year necessarily mean that the nation has lost interest in politics in general? Many would argue that this is indeed the case. I do not agree. The abject apathy that is taking hold of (especially young) South Africans concerning our country’s formal political processes is an issue widely researched and debated. Apathy is essentially having no feeling or connection to a situation or a complete lack of desire or interest to act or participate. Youth find the formal political processes frustrating, alienating, and less likely to yield desired results, consequently the evident apathy. More and more older South Africans are joining them in these attitudes and therefore have developed feelings of apathy of their own. However, apathy towards the formal political process and politicians (elections and electorates) does not mean that South Africans are not interested in politics in general. To be indifferent is to decide to show no interest and to not care or have any opinion about an issue, situation, or event. It differs from apathy because sufferings, experience and disappointment breeds apathy which is therefore not a decision, but a condition. Indifference towards the Sona 2023 is a decision South Africans make, but their interest, involvement and participation in civic organisations and representative processes remains vibrant. Therein lies our strength and in my opinion, the revitalisation of grassroots influence on South African politics.

So, if you have better things to do on the evening of the 9 February 2023, go and do them. Spend the time with community members talking about what can be done where you live to help each other and hold your officials accountable. It might also be your group’s turn for a blackout, so spend the precious time with loved ones around a candle or that rechargeable LED light. Do not feel any guilt or that you are missing out. You are not apathetic, merely indifferent. An understandable choice.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept